Literature DB >> 1372802

Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments. Epitope mapping by cDNA expression.

B Nilsson1, D Grossberger, K Nilsson Ekdahl, P Riegert, D J Becherer, U R Nilsson, J D Lambris.   

Abstract

In previous studies a subset of complement-component-C3 (C3) epitopes, C3(D), expressed in denatured and surface-bound C3 and C3 fragments, has been described. These epitopes were detected by antibodies raised against denatured C3. In the present study we used a cDNA expression strategy to localize epitopes recognized by monoclonal and polyclonal anti-C3(D) antibodies. First, DNAse I digestion of C3 cDNA was used to generate 200-300 bp fragments. These cDNA fragments were expressed as beta-galactosidase-C3 fusion proteins using the lambda gt11 vector. The fusion proteins were tested by Western-blot analysis for reactivity with monoclonal and polyclonal anti-C3 antibodies, and the location of the epitopes were determined by sequencing the cDNA fragments. Affinity-purified polyclonal anti-C3(D) antibodies specific for denatured C3 reacted strongly with the C3 fusion fragments corresponding to segments of the 40 kDa subunit of C3c (residues 1477-1510) and the C3d fragment (residues 1117-1155 and 1234-1294) of C3. Adsorption of the polyclonal antibodies with a mixture of EAC3b and EAC3bi (degradation fragments of C3 bound to sheep erythrocytes) abolished binding to fusion proteins spanning the C3d region, but not the 40 kDa fragment of C3c. No effect was seen with the corresponding soluble C3 fragments. The monoclonal anti-C3(D) antibodies (mAbs) 7D326.1 and 7D331.1, specific for EAC3b and EAC3bi, bound to a fusion protein corresponding to amino acid residues 1312-1404, whereas mAb 7D9.2, specific for EAC3d, reacted with a fusion protein spanning amino acid residues 1082-1118. mAbs 4SD11.1 and 4SD18.1, which did not bind to any physiological C3 fragment, detected a fusion protein covering residues 1477-1510. In summary, the segments of C3 represented by amino acid residues 1082-1118, 1117-1155, 1234-1294 and 1312-1404 accommodate C3(D) epitopes that are expressed by erythrocyte-bound C3 fragments, but not by the corresponding fluid-phase fragment, whereas the segments spanning residues 973-1026 and 1477-1510 contain C3(D) epitopes that are exposed exclusively in denatured C3 and therefore hidden in physiological fragments of the protein.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1372802      PMCID: PMC1130846          DOI: 10.1042/bj2820715

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  44 in total

Review 1.  Molecular aspects of C3 interactions and structural/functional analysis of C3 from different species.

Authors:  J D Becherer; J Alsenz; J D Lambris
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Human complement component C3: cDNA coding sequence and derived primary structure.

Authors:  M H de Bruijn; G H Fey
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

3.  Monoclonal antibodies as probes of conformational changes in protein-engineered cytochrome c.

Authors:  J F Collawn; C J Wallace; A E Proudfoot; Y Paterson
Journal:  J Biol Chem       Date:  1988-06-25       Impact factor: 5.157

Review 4.  Membrane complement receptors specific for bound fragments of C3.

Authors:  G D Ross; M E Medof
Journal:  Adv Immunol       Date:  1985       Impact factor: 3.543

5.  A new and fast method for preparing high quality lambda DNA suitable for sequencing.

Authors:  G Manfioletti; C Schneider
Journal:  Nucleic Acids Res       Date:  1988-04-11       Impact factor: 16.971

6.  The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.

Authors:  K J Gadd; K B Reid
Journal:  Biochem J       Date:  1981-05-01       Impact factor: 3.857

7.  Physico-chemical and antigenic properties of human C3.

Authors:  J L Molenaar; A W Helder; M A Müller; M Goris-Mulder; L S Jonker; M Brouwer; K W Pondman
Journal:  Immunochemistry       Date:  1975-05

8.  Neoantigens in complement component C3 as detected by monoclonal antibodies. Mapping of the recognized epitopes by synthetic peptides.

Authors:  B Nilsson; K Nilsson Ekdahl; D Avila; U R Nilsson; J D Lambris
Journal:  Biochem J       Date:  1990-05-15       Impact factor: 3.857

9.  Antigens of complement factor C3 involved in the interactions with factors I and H.

Authors:  B Nilsson; U R Nilsson
Journal:  Scand J Immunol       Date:  1986-03       Impact factor: 3.487

10.  Detection of disulphide bonds and localization of interchain linkages in the third (C3) and the fourth (C4) components of human complement.

Authors:  J Janatova
Journal:  Biochem J       Date:  1986-02-01       Impact factor: 3.857

View more
  6 in total

1.  A Robust Method to Store Complement C3 With Superior Ability to Maintain the Native Structure and Function of the Protein.

Authors:  Anna Adler; Vivek Anand Manivel; Karin Fromell; Yuji Teramura; Kristina N Ekdahl; Bo Nilsson
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

Review 2.  Structure, functions, and evolution of the third complement component and viral molecular mimicry.

Authors:  A Sahu; J O Sunyer; W T Moore; M R Sarrias; A M Soulika; J D Lambris
Journal:  Immunol Res       Date:  1998       Impact factor: 4.505

3.  Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction.

Authors:  M Pekna; L Nilsson; K Nilsson-Ekdahl; U R Nilsson; B Nilsson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

4.  Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.

Authors:  S B Laursen; S Thiel; B Teisner; U Holmskov; Y Wang; R B Sim; J C Jensenius
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

5.  Two conformational forms of target-bound iC3b that distinctively bind complement receptors 1 and 2 and two specific monoclonal antibodies.

Authors:  Ulf R Nilsson; Lillemor Funke; Bo Nilsson; Kristina N Ekdahl
Journal:  Ups J Med Sci       Date:  2010-11-11       Impact factor: 2.384

6.  Assessment of the Role of C3(H2O) in the Alternative Pathway.

Authors:  Karin Fromell; Anna Adler; Amanda Åman; Vivek Anand Manivel; Shan Huang; Claudia Dührkop; Kerstin Sandholm; Kristina N Ekdahl; Bo Nilsson
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.